Clinical Hematology International

Volume 1, Issue 3, September 2019, Pages 142 - 153

Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives

Authors
Mohammad Shahrukh Tanweer1, , Mahmoud Aljurf2, Bipin N. Savani3, Perviz K. Iqbal4, Shahrukh Hashmi2, *
1Dow Medical College Search, Dow University of Health Sciences, Karachi, Pakistan
2Oncology Center, King Faisal Specialist Hospital and Research Center Search, Riyadh, Kingdom of Saudi Arabia
3Department of Medicine, Vanderbilt University Medical Center Search, TN, USA
4Department of Medicine, King Faisal Specialist Hospital and Research Center Search, Riyadh, KSA

Mercy St. Vincent's Medical Center, Toledo, Ohio

*Corresponding author. Division of Hematology, Department of Medicine, Blood and Marrow Transplant division, Transplant Center, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA. Tel.: (+1) 507-538-3270; Fax: (+1) 507-284-4011. Email: hashmi.shahrukh@mayo.edu
Corresponding Author
Shahrukh Hashmi
Received 25 March 2019, Accepted 14 May 2019, Available Online 1 September 2019.
DOI
https://doi.org/10.2991/chi.d.190519.001How to use a DOI?
Keywords
Cervical; Cancer; Dysplasia; Transplant; Immunosuppression
Abstract

Female recipients of hematopoietic cell transplant (HCT) may develop lower genital tract (LGT) dysplasia or new malignancies. A comprehensive systematic review to delineate the occurrence and risk factors for post-HCT LGT precancer and cancer in women was conducted via electronic search of the Cochrane Library, PubMed, Embase, Wiley Online Library, from 1990 to 2018. All studies on the risk, presentation, or incidence of LGT (cervix, vulva, vagina) precancer or cancer post-HCT were included. Reviews, case reports, meta-analysis, book chapters, and studies without the relevant clinical outcomes were excluded. Post-HCT incidence and risk factors for developing LGT precancer or cancer were assessed and determined. Twenty-two out of the original 344 studies met the selection criteria. The risk of LGT cancers in allo-HCT recipients was found to be significantly higher than in the general population, with the standardized incidence ratios of 1.5–48 for cervical cancer and from 19 to 287 for dysplasia. Our review portrays an increased risk of premalignant and malignant neoplasms of female LGT, which have an incompletely described epidemiology and outcomes. Similar to other immunocompromised states, HCT recipients require specific cervical screening guidelines and can greatly benefit from HPV vaccinations. However, there is a lack of prospective data regarding optimum cervical screening in HCT recipients and limited programs offer HPV vaccinations worldwide.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
1 - 3
Pages
142 - 153
Publication Date
2019/09/01
ISSN (Online)
2590-0048
DOI
https://doi.org/10.2991/chi.d.190519.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Mohammad Shahrukh Tanweer
AU  - Mahmoud Aljurf
AU  - Bipin N. Savani
AU  - Perviz K. Iqbal
AU  - Shahrukh Hashmi
PY  - 2019
DA  - 2019/09/01
TI  - Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives
JO  - Clinical Hematology International
SP  - 142
EP  - 153
VL  - 1
IS  - 3
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190519.001
DO  - https://doi.org/10.2991/chi.d.190519.001
ID  - Tanweer2019
ER  -